Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

Mathematical and Experimental Validation of Flux Dialysis Method: An Improved Approach to Measure Unbound Fraction for Compounds with High Protein Binding and Other Challenging Properties

(2018) J. Cory Kalvass et al.   DRUG METABOLISM AND DISPOSITION

Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases

(2018) Gautham Gampa et al.   DRUG METABOLISM AND DISPOSITION

Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study

(2017) Courtney Kromer et al.   JOURNAL OF NEURO-ONCOLOGY

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma

(2017) Janice K. Laramy et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

(2017) Sani H. Kizilbash et al.   MOLECULAR CANCER THERAPEUTICS

The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood–brain barrier (BBB) permeability

(2017) Karthik Lingineni et al.   MOLECULAR DIVERSITY

Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels

(2017) Timothy P Heffron   NEURO-ONCOLOGY

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

(2017) Gautham Gampa et al.   PHARMACOLOGICAL RESEARCH

Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities

(2017) Robert J. McDonald et al.   RADIOLOGY

Diagnosis and Treatment of mela-noma Brain Metastasis: A Literature Review

(2017) Andrew E. Sloan et al.   Cancer Control

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases

(2016) M. Osswald et al.   CLINICAL CANCER RESEARCH

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma

(2016) Alex Kim et al.   Expert Opinion on Drug Discovery

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

(2016) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

(2016) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

(2016) Maria Menichincheri et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer

(2016) Timothy P. Heffron   JOURNAL OF MEDICINAL CHEMISTRY

Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

(2016) Giulio Metro et al.   JOURNAL OF NEURO-ONCOLOGY

Brain metastasis in breast cancer: a comprehensive literature review

(2016) Rezvan Rostami et al.   JOURNAL OF NEURO-ONCOLOGY

1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

(2016) R. Rosell et al.   Journal of Thoracic Oncology

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry

(2016) Caroline E. McCoach et al.   Journal of Thoracic Oncology

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

(2016) Dong-Wan Kim et al.   LANCET ONCOLOGY

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases

(2016) Bindiya G. Patel et al.   MELANOMA RESEARCH

ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model

(2016) R. K. Mittapalli et al.   MOLECULAR CANCER THERAPEUTICS

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

(2016) E. Ardini et al.   MOLECULAR CANCER THERAPEUTICS

Pericytes of the neurovascular unit: key functions and signaling pathways

(2016) Melanie D Sweeney et al.   NATURE NEUROSCIENCE

Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

(2016) Marc C. Chamberlain et al.   NEURO-ONCOLOGY

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

(2016) Z. Yang et al.   Science Translational Medicine

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

(2016) Ryohei Katayama et al.   EBioMedicine

Emerging Strategies for Treating Brain Metastases from Breast Cancer

(2015) David P. Kodack et al.   CANCER CELL

Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition

(2015) Shaojun Shi et al.   CURRENT DRUG METABOLISM

Brain barriers: Crosstalk between complex tight junctions and adherens junctions

(2015) Silvia Tietz et al.   JOURNAL OF CELL BIOLOGY

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

(2015) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

(2015) Qingbei Zeng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study

(2015) Minesh P. Mehta et al.   JOURNAL OF NEURO-ONCOLOGY

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

(2015) Petra Hoffknecht et al.   Journal of Thoracic Oncology

Response assessment criteria for brain metastases: proposal from the RANO group

(2015) Nancy U Lin et al.   LANCET ONCOLOGY

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

(2015) Deepa Rangachari et al.   LUNG CANCER

Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma

(2015) Lilia Sakji-Dupré et al.   MELANOMA RESEARCH

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

(2015) K. E. Parrish et al.   MOLECULAR CANCER THERAPEUTICS

Abstract B168: The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model

(2015) Keith Mikule et al.   MOLECULAR CANCER THERAPEUTICS

Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging

(2015) Robert J. McDonald et al.   RADIOLOGY

Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain

(2015) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

(2015) P. K. Brastianos et al.   Cancer Discovery

Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases

(2014) S. Gori et al.   ANNALS OF ONCOLOGY

Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis

(2014) Wenwen Zhang et al.   BMC CANCER

Metastatic breast cancer subtypes and central nervous system metastases

(2014) C. Aversa et al.   BREAST

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

(2014) Tatsushi Kodama et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

(2014) F. Lin et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

(2014) Sven Wind et al.   CLINICAL DRUG INVESTIGATION

Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

(2014) Ted W. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

PARP Inhibitors as P-glyoprotein Substrates

(2014) Denise Lawlor et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

(2014) Shirish M Gadgeel et al.   LANCET ONCOLOGY

Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer

(2014) T. Kodama et al.   MOLECULAR CANCER THERAPEUTICS

Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib

(2014) Edna F. Choo et al.   MOLECULAR PHARMACEUTICS

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study

(2014) Aki Morikawa et al.   NEURO-ONCOLOGY

Brain metastasis from renal cell carcinoma

(2014) O. Bennani et al.   NEUROCHIRURGIE

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?

(2013) Jörg Kreuter   ADVANCED DRUG DELIVERY REVIEWS

Molecularly targeted therapies for metastatic triple-negative breast cancer

(2013) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

Patterns of response and progression in patients withBRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

(2013) Mary W. F . Azer et al.   CANCER

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

(2013) Seng Chuan Tang et al.   INTERNATIONAL JOURNAL OF CANCER

Blood–brain barrier structure and function and the challenges for CNS drug delivery

(2013) N. Joan Abbott   JOURNAL OF INHERITED METABOLIC DISEASE

Vemurafenib and radiation therapy in melanoma brain metastases

(2013) Ashwatha Narayana et al.   JOURNAL OF NEURO-ONCOLOGY

Utility of CSF in translational neuroscience

(2013) Elizabeth C. M. de Lange   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid

(2013) Joost Westerhout et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

(2013) Yan Chen et al.   LUNG CANCER

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study

(2013) D. H. Pafundi et al.   NEURO-ONCOLOGY

Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial

(2013) P. D. Brown et al.   NEURO-ONCOLOGY

Melanoma metastasis: new concepts and evolving paradigms

(2013) W E Damsky et al.   ONCOGENE

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

(2013) Carey K. Anders et al.   PLoS One

SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition

(2013) Jesse E. Hanson et al.   PLoS One

Melanoma Brain Metastases: an Unmet Challenge in the Era of Active Therapy

(2013) Vikram Gorantla et al.   Current Oncology Reports

Brain metastases: pathobiology and emerging targeted therapies

(2012) Matthias Preusser et al.   ACTA NEUROPATHOLOGICA

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations

(2012) S. Heon et al.   CLINICAL CANCER RESEARCH

Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

(2012) Arkadiusz Z. Dudek et al.   Clinical Genitourinary Cancer

Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up

(2012) Sagar Agarwal et al.   CURRENT PHARMACEUTICAL DESIGN

The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α

(2012) Timothy P. Heffron et al.   JOURNAL OF MEDICINAL CHEMISTRY

Examination of blood–brain barrier (BBB) integrity in a mouse brain tumor model

(2012) Ngoc H. On et al.   JOURNAL OF NEURO-ONCOLOGY

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

(2012) Thomas Bachelot et al.   LANCET ONCOLOGY

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

(2012) D. P. Fitzgerald et al.   MOLECULAR CANCER THERAPEUTICS

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

(2012) Selvi Durmus et al.   MOLECULAR PHARMACEUTICS

Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma

(2012) O. Bailon et al.   NEURO-ONCOLOGY

Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data

(2012) Faith G. Davis et al.   NEURO-ONCOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

Improving the prediction of the brain disposition for orally administered drugs using BDDCS

(2011) Fabio Broccatelli et al.   ADVANCED DRUG DELIVERY REVIEWS

Distribution of metastatic sites in renal cell carcinoma: a population-based analysis

(2011) M. Bianchi et al.   ANNALS OF ONCOLOGY

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

(2011) J. J. Luke et al.   CLINICAL CANCER RESEARCH

Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

(2011) Thanyanan Reungwetwattana et al.   Clinical Lung Cancer

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

(2011) B. Poller et al.   DRUG METABOLISM AND DISPOSITION

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

(2011) Sagar Agarwal et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

(2011) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases

(2011) Paul W. Sperduto et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors

(2011) Yasuo Uchida et al.   JOURNAL OF NEUROCHEMISTRY

Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate

(2011) H. Kodaira et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Vemurafenib for Melanoma Metastases to the Brain

(2011) Nicole M. Rochet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

(2011) Kunal S. Taskar et al.   PHARMACEUTICAL RESEARCH

Epidemiology of Brain Metastases

(2011) Lakshmi Nayak et al.   Current Oncology Reports

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

(2010) Martin E. Gore et al.   CANCER

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival

(2010) Jan Zakrzewski et al.   CANCER

The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases

(2010) Carey K. Anders et al.   CANCER

Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

(2010) P. R. Lockman et al.   CLINICAL CANCER RESEARCH

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation

(2010) M. A. Elmeliegy et al.   CLINICAL CANCER RESEARCH

Drug-Drug Interactions between Oral Antiepileptics and Oral Anticancer Drugs: Implications to Clinicians

(2010) Yin Ting Cheung et al.   EUROPEAN NEUROLOGY

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

(2010) Nienke A. de Vries et al.   INVESTIGATIONAL NEW DRUGS

Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

(2010) Martin Kocher et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

(2010) S. Agarwal et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

(2010) Yosuke Togashi et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival among women with triple receptor-negative breast cancer and brain metastases

(2009) S. Dawood et al.   ANNALS OF ONCOLOGY

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks

(2009) D. Palmieri et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases

(2009) Brian Leyland-Jones   JOURNAL OF CLINICAL ONCOLOGY

Interplay of Transporters and Enzymes in Drug and Metabolite Processing

(2009) K. Sandy Pang et al.   MOLECULAR PHARMACEUTICS

Real-time imaging reveals the single steps of brain metastasis formation

(2009) Yvonne Kienast et al.   NATURE MEDICINE

Structure and function of the blood–brain barrier

(2009) N. Joan Abbott et al.   NEUROBIOLOGY OF DISEASE

The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters

(2009) Olena Kis et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

Drug interactions between chemotherapeutic regimens and antiepileptics

(2008) K YAP et al.   CLINICAL THERAPEUTICS

Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid

(2008) X. Liu et al.   DRUG METABOLISM AND DISPOSITION

MRP (ABCC) Transporters-Mediated Efflux of Anti-HIV Drugs, Saquinavir and Zidovudine, from Human Endothelial Cells

(2008) Mark Eilers et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2008) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Progress in Brain Penetration Evaluation in Drug Discovery and Development

(2008) X. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS